Company intelligence / Profile preview
Metabolic Solutions Development Company
Kalamazoo, Michigan, United Statesmsdrx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has been conducting Phase 2 clinical trials for their lead compounds MSDC-0160 and MSDC-0602K for type 2 diabetes. MSDC-0602K is also being studied for NASH (Non-alcoholic steatohepatitis).
- Therapeutic areas
- EndocrinologyNeurologyMetabolic Disorders
- Modalities
- Small molecules, specifically PPAR-sparing thiazolidinediones
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cirius Therapeutics
Beyond the preview
Go deeper on Metabolic Solutions Development Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metabolic Solutions Development Company.